The Laryngoscope · 2026
Perineural Invasion and Survival in Pembrolizumab-Treated Head and Neck Squamous Cell Carcinoma.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Truong Angeline A, Ho Savinnie, Lee Rex H, Wu Xin, Kang Hyunseok, El-Sayed Ivan H, George Jonathan R, Heaton Chase M, Likhterov Ilya, Xu Mary Jue, Ha Patrick K, Algazi Alain P, Wai Katherine C
Аннотация
OBJECTIVE: To determine the relationship between perineural invasion and 6-month progression-free survival (PFS)/2-year overall survival (OS) among patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) on pembrolizumab.
METHODS: This study was a retrospective, observational study performed at a tertiary care academic center. Participants included patients with oral cavity, oropharynx, hypopharynx, and laryngeal head and neck squamous cell carcinoma who began pembrolizumab treatment at UCSF between May 2016 and May 2022. The primary outcome was 6-month progression-free survival and 6-month time-to-progression (TTP). The secondary outcome was 2-year overall survival. Disease progression was determined using radiographic criteria, adopted from the Response Evaluation Criteria in Solid Tumors.
RESULTS: One hundred and thirty-three patients with HNSCC were included. Immune checkpoint inhibitor (ICI) indication was recurrence/metastasis for all patients. Forty (30%) patients had perineural invasion. On univariate analysis, patients with perineural invasion were more likely to have worse 6-month PFS (p = 0.011). After controlling for number of metastatic organs, receipt of concurrent systemic therapy, age, and PDL-1 status, presence of perineural invasion was associated with worse 6-month PFS [HR 3.33 (1.32, 8.41), p = 0.011] and 6-month time to progression (TTP) [HR 2.14 (1.09, 7.38), p = 0.032], but was not significantly associated with 2-year OS [HR 1.35 (0.57, 3.19), p = 0.498].
CONCLUSION: Presence of perineural invasion is associated with poorer 6-month progression-free survival on ICI in patients with HNSCC. Future studies should further explore how perineural invasion may alter response to immunotherapy.
METHODS: This study was a retrospective, observational study performed at a tertiary care academic center. Participants included patients with oral cavity, oropharynx, hypopharynx, and laryngeal head and neck squamous cell carcinoma who began pembrolizumab treatment at UCSF between May 2016 and May 2022. The primary outcome was 6-month progression-free survival and 6-month time-to-progression (TTP). The secondary outcome was 2-year overall survival. Disease progression was determined using radiographic criteria, adopted from the Response Evaluation Criteria in Solid Tumors.
RESULTS: One hundred and thirty-three patients with HNSCC were included. Immune checkpoint inhibitor (ICI) indication was recurrence/metastasis for all patients. Forty (30%) patients had perineural invasion. On univariate analysis, patients with perineural invasion were more likely to have worse 6-month PFS (p = 0.011). After controlling for number of metastatic organs, receipt of concurrent systemic therapy, age, and PDL-1 status, presence of perineural invasion was associated with worse 6-month PFS [HR 3.33 (1.32, 8.41), p = 0.011] and 6-month time to progression (TTP) [HR 2.14 (1.09, 7.38), p = 0.032], but was not significantly associated with 2-year OS [HR 1.35 (0.57, 3.19), p = 0.498].
CONCLUSION: Presence of perineural invasion is associated with poorer 6-month progression-free survival on ICI in patients with HNSCC. Future studies should further explore how perineural invasion may alter response to immunotherapy.
Предметные рубрики MeSH
HumansMaleFemaleRetrospective StudiesSquamous Cell Carcinoma of Head and NeckMiddle AgedAntibodies, Monoclonal, HumanizedNeoplasm InvasivenessAgedHead and Neck NeoplasmsAdultAntineoplastic Agents, ImmunologicalProgression-Free SurvivalNeoplasm Recurrence, LocalAged, 80 and overPeripheral NervesImmune Checkpoint Inhibitors